Company intelligence / Profile preview

GRIN Therapeutics, Inc.

New York, New York, United Statesgrintherapeutics.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Radiprodil showed positive results in Phase 1b Honeycomb trial, with patients experiencing a median 86% reduction in countable motor seizure frequency. The drug appeared generally well-tolerated, with 71% of patients having greater than 50% reduction in seizures. The company received FDA Breakthrough Therapy designation in February 2025 and Orphan Drug designation in March 2025 for radiprodil.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules (specifically radiprodil, a negative allosteric modulator)
Industry: Biotech

Drug pipeline

1 asset

radiprodil

Beyond the preview

Go deeper on GRIN Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRIN Therapeutics, Inc..